Context Therapeutics Inc. (CNTX) NASDAQ
2.72
+0.07(+2.64%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Context Therapeutics Inc.
Address
2001 Market Street
Philadelphia, PA 19103
United States of America (the)
Phone
267 225 7416
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
October 20, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | 765,596 | 1984 |
| Karen Chagin | Chief Medical Officer | 26,610 | N/A |
| Alex C. Levit | Chief Legal Officer & Corporate Secretary | 541,334 | 1979 |
| Jennifer Minai-Azary | Chief Financial Officer & Treasurer | 564,090 | 1978 |
| Christopher Beck | Senior Vice President of Operations | 0 | N/A |
| Jeffrey Liebman | Associate Director of Accounting | 0 | N/A |
| Jennifer Dashnau | Senior Vice President of Technical Operations | 0 | N/A |
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
